Vivos Therapeutics Inc
VVOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.12M
Close$
Share Statistics
| Market cap | $3.12 Million |
|---|---|
| Enterprise Value | $13.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.06 |
| Beta | 6.09 |
| Outstanding Shares | 17,681,945 |
Return
| Return on Equity | 668.86% |
|---|---|
| Return on Assets | -105.69% |
| Return on Invested Capital | -615.31% |
Valuation & Multiples
| P/E Ratio | -0.11 |
|---|---|
| PEG | -1.17 |
| Price to Sales | 0.17 |
| Price to Book Ratio | -0.17 |
| Enterprise Value to Revenue | 0.65 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.9 |
| Debt to Equity | -3.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$5.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$5.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.63%▼ 8.82% |
|---|---|
| Total Invested | $242,880▼ 88.69% |
| Investors Holding | 22▼ 1.00% |
ESG Score
No data
About Vivos Therapeutics Inc
115 employeesVivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that...